<DOC>
	<DOCNO>NCT02490488</DOCNO>
	<brief_summary>The objective evaluate efficacy safety masitinib combination gemcitabine refractory ovarian cancer patient .</brief_summary>
	<brief_title>Masitinib Ovarian Cancer</brief_title>
	<detailed_description>Masitinib Mesylate novel tyrosine kinase inhibitor mainly target c-Kit PDGF receptor . C-KIT platelet-derived growth factor receptor ( PDGF-PDGFR ) , promote tumour cell growth angiogenesis find over-expressed 70 % ovarian cancer . Masitinib exhibit anti-tumoral immunotherapy activity vivo potential extend overall survival .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Main inclusion criterion : 1 . Female patient , histologically cytologically confirm advanced / metastatic epithelial ovarian cancer either : refractory first line platinum treatment ( define progressive disease receive persistent disease platinumbased therapy , accord GOG ) , candidate third line treatment . 2 . Patient recover acute toxic side effect prior therapy surgical procedure grade ≤1 National Cancer InstituteCommon Toxicity Criteria ( NCICTCAE v4.02 ) , except laboratory value 3 . Patient least one target lesion measure one dimension , accord Response Evaluation Criteria Solid Tumors ( RECIST ) 4 . ECOG Performance status ≤ 2 5 . Patient adequate organ function per laboratory test evaluations 6 . Patient life expectancy &gt; 3 month 7 . Patient weight &gt; 40 kg BMI &gt; 18 8 . Female patient ≥ 18 year 9 . Patient nutritional risk index ( NRI ) ≥ 83.5 , i.e . moderate malnutrition ; 10 . Female patient childbearing potential ( enter study menstrual period negative pregnancy test ) , agree use two method ( one patient one partner ) medically acceptable form contraception study 3 month last treatment intake . Main exclusion criterion : 1 . Patient intolerant gemcitabine 2 . Patient recover significant treatment toxicity prior baseline ( ≥Grade 2 ) 3 . Patient present serious cardiac disorder define protocol 4 . Pregnant nursing female patient 5 . Patient active central nervous system ( CNS ) metastasis history CNS metastasis 6 . Patient treat cancer epithelial ovarian cancer within 5 year enrolment , exception basal cell carcinoma cervical cancer situ WASHOUT : 1 . Patient least 4 week major surgery ( baseline/W0 ) 2 . Patient treat investigational agent within 4 week prior baseline 3 . Patient systemic chemotherapy within 4 week baseline 4 . Patient radiotherapy within 4 week baseline</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>ovarian cancer</keyword>
</DOC>